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Abstract
Blood pressure (BP) is a heritable trait1 influenced by multiple biological pathways and is
responsive to environmental stimuli. Over one billion people worldwide have hypertension (BP
≥140 mm Hg systolic [SBP] or ≥90 mm Hg diastolic [DBP])2. Even small increments in BP are
associated with increased risk of cardiovascular events3. This genome-wide association study of
SBP and DBP, which used a multi-stage design in 200,000 individuals of European descent,
identified 16 novel loci: six of these loci contain genes previously known or suspected to regulate
BP (GUCY1A3-GUCY1B3; NPR3-C5orf23; ADM; FURIN-FES; GOSR2; GNAS-EDN3); the
other 10 provide new clues to BP physiology. A genetic risk score based on 29 genome-wide
significant variants was associated with hypertension, left ventricular wall thickness, stroke, and
coronary artery disease, but not kidney disease or kidney function. We also observed associations
with BP in East Asian, South Asian, and African ancestry individuals. Our findings provide new
insights into the genetics and biology of BP, and suggest novel potential therapeutic pathways for
cardiovascular disease prevention.
Genetic approaches have advanced the understanding of biological pathways underlying
inter-individual variation in BP. For example, studies of rare Mendelian BP disorders have
identified multiple defects in renal sodium handling pathways4. More recently two genome-
wide association studies (GWAS), each of >25,000 individuals of European-ancestry,
identified 13 loci associated with SBP, DBP, and hypertension5,6. We now report results of a
new meta-analysis of GWAS data that includes staged follow-up genotyping to identify
additional BP loci.
Primary analyses evaluated associations between 2.5 million genotyped or imputed single
nucleotide polymorphisms (SNPs) and SBP and DBP in 69,395 individuals of European
ancestry from 29 studies (Supplementary Materials Sections 1–3, Supplementary Tables 1–
2). Following GWAS meta-analysis, we conducted a three-stage validation experiment that
made efficient use of available genotyping resources, to follow up top signals in up to
133,661 additional individuals of European descent (Supplementary Fig. 1 and
Supplementary Materials Section 4). Twenty-nine independent SNPs at 28 loci were
significantly associated with SBP, DBP, or both in the meta-analysis combining discovery
and follow up data (Fig. 1, Table 1, Supplementary Figs 2–3, Supplementary Tables 3–5).
All 29 SNPs attained association P <5×10−9, an order of magnitude beyond the standard
genome-wide significance level for a single stage experiment (Table 1).
Sixteen of these 29 associations were novel (Table 1). Two associations were near the
FURIN and GOSR2 genes; prior targeted analyses of variants in these genes suggested they
Note added in proof: Since this manuscript was submitted, Kato et al published a BP GWAS in East Asians that identified a SNP
highly correlated to the SNP we report at the NPR3-c5orf23 locus28.
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may be BP loci7,8. At the CACNB2 locus we validated association for a previously
reported6 SNP rs4373814 and detected a novel independent association for rs1813353
(pairwise r2 =0.015 in HapMap CEU). Of our 13 previously reported associations5,6, only
the association at PLCD3 was not supported by the current results (Supplementary Table 4).
Some of the associations are in or near genes involved in pathways known to influence BP
(NPR3, GUCY1A3-GUCY1B3, ADM, GNAS-EDN3, NPPA-NPPB, and CYP17A1;
Supplementary Fig. 4). Twenty-two of the 28 loci did not contain genes that were a priori
strong biological candidates.
As expected from prior BP GWAS results, the effects of the novel variants on SBP and DBP
were small (Fig. 1 and Table 1). For all variants, the observed directions of effects were
concordant for SBP, DBP, and hypertension (Fig. 1, Table 1, Supplementary Fig. 3). Among
the genes at the genome-wide significant loci, only CYP17A1, previously implicated in
Mendelian congenital adrenal hyperplasia and hypertension, is known to harbour rare
variants that have large effects on BP9.
We performed several analyses to identify potential causal alleles and mechanisms. First, we
looked up the 29 genome-wide significant index SNPs and their close proxies (r2>0.8)
among cis-acting expression SNP (eSNP) results from multiple tissues (Supplementary
Materials Section 5). For 13/29 index SNPs, we found association between nearby eSNP
variants and expression level of at least one gene transcript (10−4 > p > 10−51,
Supplementary Table 6). In 5 cases, the index BP SNP and the best eSNP from a genome-
wide survey were identical, highlighting potential mediators of the SNP-BP associations.
Second, because changes in protein sequence are strong a priori candidates to be functional,
we sought non-synonymous coding SNPs that were in high LD (r2 >0.8) with the 29 index
SNPs. We identified such SNPsat 8 loci (Table 1, Supplementary Materials Section 6,
Supplementary Table 7). In addition we performed analyses testing for differences in genetic
effect according to body mass index (BMI) or sex, and analyses of copy number variants,
pathway enrichment, and metabolomic data, but we did not find any statistically significant
results (Supplementary Materials Sections 7–9, Supplementary Tables 8–10).
We evaluated whether the BP variants we identified in Europeans were associated with BP
in individuals of East Asian (N=29,719), South Asian (N=23,977), and African (N=19,775)
ancestries (Table 1, Supplementary Tables 11–13). We found significant associations in
individuals of East Asian ancestry for SNPs at 9 loci and in individuals of South Asian
ancestry for SNPs at 6 loci; some have been reported previously (Supplementary Tables 12
and 15). The lack of significant association for individual SNPs may reflect small sample
sizes, differences in allele frequencies or LD patterns, imprecise imputation for some
ancestries using existing reference samples, or a genuinely different underlying genetic
architecture. Because of limited power to detect effects of individual variants in the smaller
non-European samples, we created genetic risk scores for SBP and DBP incorporating all 29
BP variants weighted according to effect sizes observed in the European samples. In each
non-European ancestry group, risk scores were strongly associated with SBP (P=1.1×10−40
in East Asian, P=2.9×10−13 in South Asian, P=9.8×10−4 in African ancestry individuals) and
DBP (P=2.9×10−48, P=9.5×10−15, and P=5.3×10−5, respectively; Supplementary Table 13).
We also created a genetic risk score to assess association of the variants in aggregate with
hypertension and with clinical measures of hypertensive complications including left
ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent
stroke, prevalent coronary artery disease (CAD), kidney disease, and measures of kidney
function, using results from other GWAS consortia (Table 2, Supplementary Materials
Sections 10–11, Supplementary Table 14). The risk score was weighted using the average of
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SBP and DBP effects for the 29 SNPs. In an independent sample of 23,294 women10, an
increase of 1 standard deviation in the genetic risk score was associated with a 21% increase
in the odds of hypertension (95% CI 19%–28%; Table 2, Supplementary Table 14). Among
individuals in the top decile of the risk score, the prevalence of hypertension was 29%
compared with 16% in the bottom decile (odds ratio 2.09, 95% CI 1.86–2.36). Similar
results were observed in an independent hypertension case-control sample (Table 2). In our
study, individuals in the top compared to bottom quintiles of genetic risk score differed by
4.6 mm Hg SBP and 3.0 mm Hg DBP, differences that approach population-averaged BP
treatment effects for a single antihypertensive agent11. Epidemiologic data have shown that
differences in SBP and DBP of this magnitude, across the population range of BP, are
associated with an increase in cardiovascular disease risk3. Consistent with this and in line
with findings from randomized trials of BP-lowering medication in hypertensive
patients12,13, the genetic risk score was positively associated with left ventricular wall
thickness (P=6.0×10−6), occurrence of stroke (P=3.3×10−5) and CAD (P=8.1×10−29). The
same genetic risk score was not, however, significantly associated with chronic kidney
disease or measures of kidney function, even though these renal outcomes were available in
a similar sample size as for the other outcomes (Table 2). The absence of association with
kidney phenotypes could be explained by a weaker causal relation of BP with kidney
phenotypes than with CAD and stroke. This finding is consistent with the mismatch between
observational data that show a positive association of BP with kidney disease, and clinical
trial data that show inconsistent evidence of benefit of BP lowering on kidney disease
prevention in patients with hypertension14. Thus, several lines of evidence converge to
suggest that BP elevation may in part be a consequence rather than a cause of sub-clinical
kidney disease.
Our discovery meta-analysis (Supplementary Fig. 2) suggests an excess of modestly
significant (10−5 <P <10−2) associations likely arising from common BP variants of small
effect. By dividing our principal GWAS dataset into non-overlapping discovery (N≈56,000)
and validation (N≈14,000) subsets, we found robust evidence for the existence of such
undetected common variants (Supplementary Fig. 5, Supplementary Materials Section 12).
We estimate15 that there are 116 (95% CI 57–174) independent BP variants with effect sizes
similar to those reported here, which collectively explain ≈2.2% of the phenotypic variance
for SBP and DBP, compared with 0.9% explained by the 29 associations discovered thus far
(Supplementary Fig. 6, Supplementary Materials Section 13).
Most of the 28 BP loci harbour multiple genes (Supplementary Table 15, Supplementary
Fig. 4), and although substantial research is required to identify the specific genes and
variants responsible for these associations, several loci contain highly plausible biological
candidates. The NPPA and NPPB genes at the MTHFR-NPPB locus encode precursors for
atrial- and B-type natriuretic peptides (ANP, BNP), and previous work has identified SNPs,
modestly correlated with our index SNP at this locus, that are associated with plasma ANP,
BNP, and BP16. We found the index SNP at this locus was associated with opposite effects
on BP and on ANP/BNP levels, consistent with a model in which the variants act through
increased ANP/BNP production to lower BP16 (Supplementary Materials Section 14).
Two other loci identified in the current study harbour genes involved in natriuretic peptide
and related nitric oxide signalling pathways,17,18 both of which act to regulate cyclic
guanosine monophosphate (cGMP). The first locus contains NPR3, which encodes the
natriuretic peptide clearance receptor (NPR-C). NPR3 knockout mice exhibit reduced
clearance of circulating natriuretic peptides and lower BP19. The second locus includes
GUCY1A3 and GUCY1B3, encoding the alpha and beta subunits of soluble
guanylatecyclase (sGC); knockout of either gene in murine models results in hypertension20.
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Another locus contains ADM, encoding adrenomedullin, which has natriuretic, vasodilatory,
and BP-lowering properties21. At the GNAS-EDN3 locus, ZNF831 is closest to the index
SNP, but GNAS and EDN3 are two nearby compelling biological candidates
(Supplementary Fig. 4, Supplementary Table 15).
We identified two loci with plausible connections to BP via genes implicated in renal
physiology or kidney disease. At the first locus, SLC4A7 is an electro-neutral sodium
bicarbonate co-transporter expressed in the nephron and in vascular smooth muscle22. At the
second locus, PLCE1 (phospholipase-C-epsilon-1 isoform) is important for normal podocyte
development in the glomerulus; sequence variation in PLCE1 has been implicated in
familial nephrotic syndromes and end-stage kidney disease23.
Missense variants in two genes involved in metal ion transport were associated with BP in
our study. The first encodes a His/Asp change at amino acid 63 (H63D) in HFE and is a low
penetrance allele for hereditary hemochromatosis24. The second is an Ala/Thr
polymorphism located in exon 7 of SLC39A8, which encodes a zinc transporter that also
transports cadmium and manganese25. The same allele of SLC39A8 associated with BP in
our study has recently been associated with high-density lipoprotein (HDL) cholesterol
levels26 and BMI27 (Supplementary Table 15).
In conclusion, we have shown that 29 independent genetic variants influence BP in people
of European ancestry. The variants reside in 28 loci, 16 of which were novel, and we
confirmed association of several of them in individuals of non-European ancestry. A risk
score derived from the 29 variants was significantly associated with BP-related organ
damage and clinical cardiovascular disease, but not kidney disease. These loci improve our
understanding of the genetic architecture of BP, provide new biological insights into BP
control and may identify novel targets for the treatment of hypertension and the prevention
of cardiovascular disease.
Methods summary
Supplementary Materials provide complete methods and include the following sections:
study recruitment and phenotyping, adjustment for antihypertensive medications,
genotyping, data quality control, genotype imputation, within-cohort association analyses,
meta-analyses of discovery and validation stages, stratified analyses by sex and BMI,
identification of eSNPs and nsSNPs, metabolomic and lipidomic analyses, CNV analyses,
pathway analyses, analyses for non-European ancestries, association of a risk score with
hypertension and cardiovascular disease, estimation of numbers of undiscovered variants,
measurement of natriuretic peptides, and brief literature reviews and GWAS database
lookups of all validated BP loci.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Genome-wide –log10 P-value plots and effects for significant loci.
Genome-wide –log10 P-value plots are shown for systolic (SBP: panel a) and diastolic
(DBP: panel b). SNPs within loci reaching genome-wide significance are labeled in red for
SBP and blue for DBP (±2.5Mb of lowest P-value) and lowest P-values in the initial
genome-wide analysis as well as the results of analysis including validation data are labeled
separately. The lowest P-values in the initial GWAS are denoted as an X. The range of
different sample sizes in the final meta-analysis including the validation data are indicated
as: circle (96–140k), triangle (>140–180k), and diamond (>180–220k). SNPs near
unconfirmed loci are in black. The horizontal dotted line is P=2.5 × 10−8. Panel c shows the
effect size estimates and 95% confidence bars per BP-increasing allele of the 29 significant
variants for SBP (red) and DBP (blue). Effect sizes are expressed in mmHg/allele. GUCY =
GUCY1A3-GUCY1B3.
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